Edition:
United States

Celldex Therapeutics Inc (CLDX.OQ)

CLDX.OQ on NASDAQ Stock Exchange Capital Market

4.94USD
22 Mar 2019
Change (% chg)

$-0.20 (-3.89%)
Prev Close
$5.14
Open
$5.13
Day's High
$5.19
Day's Low
$4.86
Volume
66,147
Avg. Vol
68,684
52-wk High
$37.35
52-wk Low
$2.74

Latest Key Developments (Source: Significant Developments)

Celldex Therapeutics Reports Q4 Loss Per Share $0.03
Wednesday, 7 Mar 2018 04:01pm EST 

March 7 (Reuters) - Celldex Therapeutics Inc ::CELLDEX PROVIDES CORPORATE UPDATE AND REPORTS FULL YEAR 2017 RESULTS.Q4 LOSS PER SHARE $0.03.CELLDEX THERAPEUTICS - ANTICIPATE TOPLINE PRIMARY ENDPOINT DATA FROM METRIC STUDY OF GLEMBATUMUMAB VEDOTIN WILL BE AVAILABLE IN Q2 OF 2018.Q4 REVENUE $3.5 MILLION VERSUS $1.9 MILLION.  Full Article

Celldex Therapeutics Q3 loss per share $0.20
Tuesday, 7 Nov 2017 08:01am EST 

Nov 7 (Reuters) - Celldex Therapeutics Inc :Q3 revenue $3.9 million versus $2.2 million .Celldex reports third quarter 2017 results.Q3 revenue view $1.1 million -- Thomson Reuters I/B/E/S.Q3 loss per share $0.20.Q3 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.Celldex Therapeutics Inc - ‍ projects that topline primary endpoint data should be available in Q2 of 2018 for metric​.Celldex therapeutics inc - ‍by year-end, celldex plans to initiate an open-label phase 2 study of CDX-3379 given in combination with erbitux​.  Full Article

Celldex Therapeutics Q2 loss per share $0.23
Tuesday, 8 Aug 2017 04:01pm EDT 

Aug 8 (Reuters) - Celldex Therapeutics Inc :Celldex reports second quarter 2017 results.Q2 loss per share $0.23.Q2 revenue $3.8 million versus $2.7 million.Q2 revenue view $1 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.  Full Article

Celldex Therapeutics Q2 loss per share $0.23
Tuesday, 8 Aug 2017 04:01pm EDT 

Aug 8 (Reuters) - Celldex Therapeutics Inc :Celldex reports second quarter 2017 results.Celldex Therapeutics - Q2 revenue $3.8 million versus $1.4 million.Q2 loss per share $0.23.Q2 revenue view $1 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.  Full Article

Celldex Therapeutics promotes Sam Martin as CFO
Friday, 16 Jun 2017 08:01am EDT 

June 16 (Reuters) - Celldex Therapeutics Inc -:Celldex Therapeutics announces additions to the board of directors and senior management team.Celldex Therapeutics Inc - Sam Martin has been promoted to senior vice president and chief financial officer, effective July 1, 2017.Celldex Therapeutics Inc - Martin will assume responsibilities of Avery Catlin, who is retiring on June 30, 2017.  Full Article

Celldex reports Q1 loss per share $0.28
Tuesday, 9 May 2017 04:01pm EDT 

May 9 (Reuters) - Celldex Therapeutics Inc :Celldex reports first quarter 2017 results.Q1 loss per share $0.28.Q1 revenue $1.5 million versus $1.3 million.Q1 revenue view $923,000 -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S.  Full Article